Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-14 |
2024-09 |
-0.05 |
N/A |
N/A |
N/A |
2024-08-08 |
2024-06 |
-0.06 |
-0.04 |
0.02 |
33.33% |
2024-05-14 |
2024-03 |
-0.06 |
-0.05 |
0.01 |
16.67% |
2024-04-16 |
2023-12 |
0 |
-0.04 |
N/A |
N/A |
2023-11-09 |
2023-09 |
-0.08 |
-0.06 |
0.02 |
25.00% |
2023-08-21 |
2023-06 |
-0.08 |
-0.1 |
-0.02 |
-25.00% |
Date |
Firm |
Action |
From |
To |
2023-08-30 |
Cantor Fitzgerald |
Upgrade |
Overweight |
Overweight |
2023-08-22 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-07 |
Chardan Capital |
Upgrade |
|
Buy |
2023-04-16 |
HC Wainwright & Co. |
Upgrade |
|
Buy |
2023-04-13 |
Chardan Capital |
Upgrade |
|
Buy |
2023-02-28 |
Chardan Capital |
Upgrade |
Neutral |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-01-02 |
CRESPO JESSICA |
Officer |
163.39K |
Stock Award(Grant) |
2023-02-15 |
MUSUNURI SHANKAR PH.D |
Chief Executive Officer |
3.34M |
Conversion of Exercise of derivative security |
2023-01-02 |
UPADHYAY ARUN |
Officer |
400.08K |
Stock Award(Grant) |
2023-06-13 |
ZHANG JUNGE |
Director |
0.00 |
Purchase |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
11.81M |
6.41M |
4.60% |
2023-06-29 |
Luminus Management, LLC |
4.08M |
2.22M |
1.59% |
2023-06-29 |
GMT Capital Corp |
3.92M |
2.13M |
1.53% |
2023-06-29 |
Blackrock Inc. |
3.91M |
2.12M |
1.52% |
2023-06-29 |
JP Morgan Chase & Company |
3.04M |
1.65M |
1.19% |
2023-06-29 |
Millennium Management Llc |
3.02M |
1.64M |
1.18% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
7.60M |
4.13M |
2.96% |
2023-06-29 |
Vanguard Extended Market Index Fund |
3.06M |
1.66M |
1.19% |
2023-05-30 |
Fidelity Extended Market Index Fund |
1.07M |
490.29K |
0.42% |
2023-05-30 |
Schwab Strategic Tr-Schwab U.S. Small Cap ETF |
921.56K |
423.92K |
0.36% |
2023-05-30 |
Vanguard Health Care Index Fund |
738.21K |
339.58K |
0.29% |
2023-05-30 |
Vanguard Russell 2000 Index Fund |
597.25K |
274.74K |
0.23% |
Split |
Date |
1 : 60 |
2019-09-30 |